Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Donohue

Showing results (1-10 of 194) with videos related to

Pageof 20
Sort By:
JAMA Health Forum|January 17, 2025
Using Compounded GLP-1 Receptor Agonists-Informing and Protecting ConsumersJulie M Donohue
JAMA Health Forum|October 11, 2022
Learning From Novel Approaches to Paying for Hepatitis C Virus Medications in State Medicaid ProgramsJulie M Donohue
JAMA Health Forum|October 11, 2022
Meeting the Needs of Medicaid Beneficiaries With Substance Use Disorders in Managed CareJulie M Donohue
Psychiatric Services (Washington, D.C.)|June 9, 2005
Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnessesJulie M Donohue
The Milbank Quarterly|March 8, 2022
A Road Map to Rigor and Relevance in Pharmaceutical Policy ResearchJulie M Donohue
The New England Journal of Medicine|August 21, 2014
The impact and evolution of Medicare Part DJulie M Donohue
Addiction (Abingdon, England)|November 21, 2020
Commentary on Zhou et al. : Policy levers to reduce co-prescribing of opioids and gabapentinoids and overdose riskPatience Moyo, Julie M Donohue
JAMA|August 4, 2020
COVID-19 and School ClosuresJulie M Donohue, Elizabeth Miller
Marketing Health Services|March 30, 2005
Being directJulie M Donohue, Ernst R Berndt
The New England Journal of Medicine|May 24, 2018
Doughnuts and Discounts - Changes to Medicare Part D under the Bipartisan Budget Act of 2018Julie M Donohue, Haiden A Huskamp
Pageof 20

Showing results (1-10 of 194) with videos related to

Sort By:
Pageof 20
JAMA Health Forum|January 17, 2025
Using Compounded GLP-1 Receptor Agonists-Informing and Protecting ConsumersJulie M Donohue
JAMA Health Forum|October 11, 2022
Learning From Novel Approaches to Paying for Hepatitis C Virus Medications in State Medicaid ProgramsJulie M Donohue
JAMA Health Forum|October 11, 2022
Meeting the Needs of Medicaid Beneficiaries With Substance Use Disorders in Managed CareJulie M Donohue
Psychiatric Services (Washington, D.C.)|June 9, 2005
Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnessesJulie M Donohue
The Milbank Quarterly|March 8, 2022
A Road Map to Rigor and Relevance in Pharmaceutical Policy ResearchJulie M Donohue
The New England Journal of Medicine|August 21, 2014
The impact and evolution of Medicare Part DJulie M Donohue
Addiction (Abingdon, England)|November 21, 2020
Commentary on Zhou et al. : Policy levers to reduce co-prescribing of opioids and gabapentinoids and overdose riskPatience Moyo, Julie M Donohue
JAMA|August 4, 2020
COVID-19 and School ClosuresJulie M Donohue, Elizabeth Miller
Marketing Health Services|March 30, 2005
Being directJulie M Donohue, Ernst R Berndt
The New England Journal of Medicine|May 24, 2018
Doughnuts and Discounts - Changes to Medicare Part D under the Bipartisan Budget Act of 2018Julie M Donohue, Haiden A Huskamp
Pageof 20